The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, yet its future within the broader market now presents questions about potential yields . Generic versions are eroding patent protection , leading to concerns that betting on companies significantly dependent to Viagra's previous position could be a dangerous move